title: 6-[18F]fluoro-L-dopa and cerebral blood flow in unilaterally MPTP-treated monkeys.
abstract: Intravenous administration of 15O-labeled water and 6-[18F]-L-fluorodopa were used to assess abnormal striatal activity in monkeys after long-term recovery of unilateral lesions of the dopaminergic nigro-striatal system induced by the neurotoxin MPTP. PET data were examined in relation to behavioral and biological parameters. Cerebral blood flow and 6-[18F]-L-DOPA uptake were found to be significantly reduced in the lesioned striatum, compared to the unaffected side and to normal controls. There was no correlation between cerebral blood flow and any of the behavioral parameters. The uptake rate constant of 18F-DOPA from blood to striatum and the ratios of striatum to occipital areas were highly correlated to the concentrations of homovanillic acid in the cerebrospinal fluid of the same animals but not to the rotational behavior. This MPTP-induced model of striatal dopamine deficiency in primates presents similarities with idiopathic Parkinson's disease and may be used to evaluate the effects of dopaminergic lesions and transplants on brain function.
authors.affiliation: Clinical Brain Imaging Section, NIMH, Bethesda, MD 20892.
authors.forename: D J
authors.initials: DJ
authors.lastname: Doudet
authors.forename: R J
authors.initials: RJ
authors.lastname: Wyatt
authors.forename: E
authors.initials: E
authors.lastname: Cannon-Spoor
authors.forename: R
authors.initials: R
authors.lastname: Suddath
authors.forename: C A
authors.initials: CA
authors.lastname: McLellan
authors.forename: R M
authors.initials: RM
authors.lastname: Cohen
mesh_terms: D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine / Q000008:administration & dosage; D000818:Animals; D001479:Basal Ganglia / Q000098:blood supply / Q000378:metabolism; D001522:Behavior, Animal / Q000187:drug effects; D002343:Carotid Artery, Internal; D002560:Cerebrovascular Circulation; D003342:Corpus Striatum / Q000098:blood supply / Q000378:metabolism*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D004298:Dopamine / Q000378:metabolism; D006719:Homovanillic Acid / Q000134:cerebrospinal fluid; D006897:Hydroxyindoleacetic Acid / Q000134:cerebrospinal fluid; D007269:Injections, Intra-Arterial; D020267:MPTP Poisoning; D008253:Macaca mulatta; D008297:Male; D008734:Methoxyhydroxyphenylglycol / Q000134:cerebrospinal fluid; D009778:Occipital Lobe / Q000098:blood supply / Q000378:metabolism; D010302:Parkinson Disease, Secondary / Q000134:cerebrospinal fluid / Q000139:chemically induced / Q000503:physiopathology*; D014055:Tomography, Emission-Computed
chemical_list: C043437:fluorodopa F 18; D008734:Methoxyhydroxyphenylglycol; D006897:Hydroxyindoleacetic Acid; D004295:Dihydroxyphenylalanine; D015632:1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; D004298:Dopamine; D006719:Homovanillic Acid